MedTrace Logo

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

NCT05593653 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-04-16

Study results available
· View outcomes & findings →

Summary

The aim of this study is to determine if suvorexant can help treat the severity of insomnia and improve metabolic health in midlife women who had both insomnia and indicators of metabolic syndrome.

Conditions

Interventions

DRUG

Suvorexant

20mg taken at bedtime for 4 weeks

DRUG

Placebo

placebo taken at bedtime for 4 weeks

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Shadab Rahman, PhD MPH · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-06
Primary Completion
2025-10-24
Completion
2025-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05593653 on ClinicalTrials.gov